Gene Solutions Overview
- Year Founded
-
2006

- Status
-
Private
- Employees
-
2

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$5.33M
- Investors
-
2
Gene Solutions General Information
Description
Developer of mitochondrial therapeutics designed to enhance drug pipelines in the field of central nervous system diseases. The company's therapeutics utilize its proprietary mitochondrial genomic targets, develop accurate and effective clinical diagnostic methods for these diseases, and facilitate the development of therapeutic compounds, enabling healthcare providers to treat diseases such as Alzheimer's, Parkinson's, and Schizophrenia.
Contact Information
Website
www.mitodna.comCorporate Office
- 123 East Main Street
- Suite 5
- Charlottesville, VA 22902
- United States
Corporate Office
- 123 East Main Street
- Suite 5
- Charlottesville, VA 22902
- United States
Gene Solutions Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Later Stage VC (Series A) | 31-May-2024 | $5.33M | Completed | Generating Revenue | ||
4. Later Stage VC | 02-Oct-2015 | Completed | Generating Revenue | |||
3. Seed Round | 25-Feb-2013 | Completed | Generating Revenue | |||
2. Grant | 01-Jan-2010 | $22.5K | $350K | Completed | Generating Revenue | |
1. Angel (individual) | 26-Aug-2008 | $350K | $350K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Gene Solutions Patents
Gene Solutions Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20060194239-A1 | Using presence of mutation in nadh dehydrogenase gene as evaluative tool in diagnosis of neurodegenerative disorders | Active | 25-Feb-2005 | ||
US-20110045460-A1 | Mitochondrial complex i mutations in parkinson's disease & aging | Inactive | 25-Feb-2005 | ||
US-7537893-B2 | Using presence of mutation in nadh dehydrogenase gene as evaluative tool in diagnosis of neurodegenerative disorders | Active | 25-Feb-2005 | C12Q1/6883 |
Gene Solutions Signals
Gene Solutions Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
PIPV Capital | PE/Buyout | Minority | ||
University of Virginia | University |
Gene Solutions FAQs
-
When was Gene Solutions founded?
Gene Solutions was founded in 2006.
-
Where is Gene Solutions headquartered?
Gene Solutions is headquartered in Charlottesville, VA.
-
What is the size of Gene Solutions?
Gene Solutions has 2 total employees.
-
What industry is Gene Solutions in?
Gene Solutions’s primary industry is Biotechnology.
-
Is Gene Solutions a private or public company?
Gene Solutions is a Private company.
-
What is Gene Solutions’s current revenue?
The current revenue for Gene Solutions is
. -
How much funding has Gene Solutions raised over time?
Gene Solutions has raised $6.62M.
-
Who are Gene Solutions’s investors?
PIPV Capital and University of Virginia have invested in Gene Solutions.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »